HC Wainwright & Co. Reiterates Buy on Checkpoint Therapeutics, Maintains $34 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Checkpoint Therapeutics (NASDAQ:CKPT) and maintained a $34 price target on the stock.
December 19, 2023 | 11:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms a Buy rating on Checkpoint Therapeutics with a $34 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst can lead to increased investor confidence and a potential short-term rise in the stock price of Checkpoint Therapeutics.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100